GUMDROP : JHMI J1048 A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects with Advanced Prostate Cancer

Created by Channing Paller, last modified on Apr 14, 2012

Description:

The purpose of this dose escalation study is to determine the Maximum Tolerated Dose (MTD) and the recommended Phase 2 dose of ASG-5ME in patients with advanced prostate cancer.  Patients must have castrate resistant prostate cancer and testosterone = 50 ng/dL; must be on stable hormonal therapy if not surgically castrated; NO prednisone (or equivalent corticosteroids) > 20 mg/day

Link:

http://clinicaltrials.gov/ct2/show/NCT01228760

 

Site:

Johns Hopkins Hospital

Principal Investigator:

Mario Eisenberger, M.D.